Tivantinib - OmicsDI

Show results for

Unknown (55)
Metabolomics (2)
Clinical (1)
Transcriptomics (1)
Proteomics (1)
Genomics (1)

Organisms

Mus musculus (1)
Alphavirus (1)
Betaherpesvirinae (1)
Brassica oleracea var. oleracea (1)
Cowpox virus (1)
Coxsackievirus (1)
Cytomegalovirus (1)
Dengue virus (1)
EFO:0001352 (1)
Filoviridae (1)
Hepatitis B virus (1)
Human alphaherpesvirus 1 (1)
Human betaherpesvirus 5 (1)
Human immunodeficiency virus (1)
Human immunodeficiency virus 1 (1)
Human immunodeficiency virus 2 (1)
Influenza A virus (1)
Influenza C virus (1)
Japanese encephalitis virus (1)
Japanese encephalitis virus group (1)
Lyssavirus rabies (1)
Monkeypox virus (1)
Orthopoxvirus (1)
Orthopoxvirus vaccinia (1)
Rattus (1)
Ruditapes decussatus (1)
Staphylococcus aureus (1)
Tick-borne encephalitis virus (1)
Viruses (1)
West Nile virus (1)

Organisms

Mus musculus (1)

Repository

MetaboLights (2)
geo (1)
pride (1)
ENA (1)

Tissue

Myeloid cell (1)

Disease

Colorectal Neoplasms (1)
Acute leukemia (1)

Technology Type

Mass spectrometry (2)
Affinity purification coupled with mass spectrometry proteomics (1)
Mass Spectrometry (1)

Instrument Platform

Liquid Chromatography MS - positive - reverse phase (2)

CHEBI ID

CHEBI:8832 (2)
CHEBI:173890 (2)
CHEBI:177599 (2)
CHEBI:182449 (2)
CHEBI:182253 (2)
CHEBI:182699 (2)
CHEBI:177514 (2)
CHEBI:177688 (2)
CHEBI:182667 (2)
CHEBI:1458 (2)
CHEBI:183730 (2)
CHEBI:41674 (2)
CHEBI:165502 (2)
CHEBI:177394 (2)
CHEBI:29735 (2)
CHEBI:168507 (2)
CHEBI:75457 (2)
CHEBI:64304 (2)
CHEBI:69081 (2)
CHEBI:17252 (2)
CHEBI:88595 (2)
CHEBI:165595 (2)
CHEBI:167578 (2)
CHEBI:89871 (2)
CHEBI:172380 (2)
CHEBI:165178 (2)
CHEBI:177477 (2)
CHEBI:174791 (2)
CHEBI:87500 (2)
CHEBI:82231 (2)

Metabolite Name

(-)-Rhododendrin (2)
(2E)-2-Tridecene-4,6,8-triyn-1-ol (2)
(2E,4E,12Z)-N-Isobutyl-2,4,12-octadecatrienamide (2)
(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(2-phenylethoxy)oxane-3,4,5-triol (2)
(2R,3S,4S,5S,6R)-2-({7-hydroxy-4-[(3Z)-5-hydroxy-3-methylpent-3-en-1-yl]-4a,8,8-trimethyl-3-methylidene-decahydronaphthalen-2-yl}oxy)-6-(hydroxymethyl)oxane-3,4,5-triol (2)
(2S)-2-Amino-8-hydroxyoctanoic acid (2)
(4E)-1,7-Bis(4-hydroxyphenyl)-4-hepten-3-one (2)
(9Z)-9-Octadecenamide (2)
(E)-Dacarbazine (2)
(E)-p-coumaric acid (2)
(Z)-3-butylidene-7-hydroxyphthalide (2)
[(4Z)-5-(Methylsulfanyl)-4-penten-2-yn-1-yl]benzene (2)
1,2-Cyclohexadione (2)
1,3,7-Octanetriol (2)
1,4-Anhydro-6-O-dodecanoyl-2,3-bis-O-(2-hydroxyethyl)-D-glucitol (2)
2-linoleoylglycerol (2)
1-Monopalmitoylglycerol (2)
1-Hexyl-2-methylbenzene (2)
1-Linoleoyl-sn-glycero-3-phosphocholine (2)
1-oleoyl-sn-glycero-3-phosphoethanolamine (2)
1-Tetradecylamine (2)
2-((2E)-3,7-Dimethyl-2,6-octadienyl)-5,6-dimethoxy-3-methyl-1,4-benzenediol (2)
2-(12-Tridecyn-1-yl)furan (2)
2,2,6,6-Tetramethyl-1-piperidinol (2)
2,3,4,9-Tetrahydro-1H-beta-carboline-1,3-dicarboxylic acid (2)
2,6-di-tert-butyl-4-ethylphenol (2)
1-[2,6-Dimethyl-4-(2-methyl-2-propanyl)-3,5-dinitrophenyl]ethanone (2)
Isobutyl benzoate (2)
3-Cyclooctyl-1,1-dimethylurea (2)
(9E,12E)-9,12-Octadecadienoic acid (2)

First Public Date

2022 (1)

Study status

Completed (1)

Study type

Interventional (1)

Release Date

2019 (8)
2018 (6)
2017 (6)
2016 (6)
2015 (6)
2021 (5)
2022 (4)
2024 (3)
2020 (3)
2014 (3)
2013 (3)
2023 (1)
2012 (1)

Lab affiliation

Moffitt Cancer Center (1)

Publication date

2022 (3)
2019 (1)

Location

Italy (1)

Keyword

ERBITUX*INFUS 1FL 20ML 5MG/ML (1)
Wild type KRAS (1)
Tivantinib (1)
Cetuximab (1)

Previous page
1 / 7
You're on page 1
page 2
page 3
page 4
page 5
page 6
page 7
Next page

Sort by:

Relevance

Page size

Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia

GSK3alpha has been identified as a new target in the treatment of acute myeloid leukemia (AML). However, most GSK3 inhibitors lack specificity for GSK3alpha over GSK3beta and other kinases. We have previously shown in lung cancer cells that GSK3alpha and to a lesser extent GSK3beta are inhibited by ...

ORGANISM(S): Homo sapiens (Human)

2019-01-29 | PXD010217 | Pride